Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Acne
Announcements and latest updates

Right Decision Service newsletter: March 2024

Welcome to the Right Decision Service (RDS) newsletter for March 2024. Please forward this newsletter to others who may be interested. They can contact olivia.graham@nhs.scot to be added to the circulation list.

Promotion and communication resources

Promotional flyers are now available in the Learning and Support area of RDS:

What is RDS and what impact does it have? (infographic)

General RDS flyer

Being a partner in my care: Realistic medicine app for citizens

Managing medicines for patients and carers app

Home care decisions app

Child protection app (South Lanarkshire HSCP)

All except the infographic are also available as editable Word versions. Please contact his.decisionsupport@nhs.scot  if you would like Word versions.  

Redesign and improvements to RDS

Search and browse improvements are progressing well and the plan is still to release these in mid-May.  The first stages of work on archiving and version control are complete. User stories (requirements) are being defined for:

  • Deep linking to individual toolkit URLs/QR codes
  • Translating content from a structured Word document directly into RDS
  • Capability to review and edit changes made to shared content

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

A big thank you to all of you who have completed our Impact and Value questionnaire. The data from this will be really helpful in informing the first draft of the business case for long term provision of the RDS. This will be reviewed by the National Advisory Board for RDS later this month.

We welcome further responses. If you haven’t yet completed the survey, please follow this link, and please encourage other RDS toolkit leads and users to do so.

New toolkits

A few examples of toolkits published to live in the last month:

 

Toolkits in development

Some of the toolkits the RDS team are currently working on:

  • Updates to the Respiratory prescribing guidance and Manage Medicines for patients and carers toolkits
  • Respiratory Managed Clinical Network Pathways
  • Child abuse pathways in NHS Tayside
  • Patient information leaflet collection in NHS Borders
  • Referral management toolkit for NHS Borders
  • NHS Lothian – Infectious diseases; Acute oncology guidelines; Royal Infirmary of Edinburgh Emergency Care.

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Learning opportunities

The RDS Learning working group is progressing with developing training resources for editors, and intend to have resources to share by end of June. This includes resources for:

  • Each stage of the development journey for RDS toolkits – Scoping to Implementation/Evaluation and Maintenance.
  • RDS content governance.
  • Core functionality – learning bytes.

 

Editor webinars

Just a reminder that we are offering webinars for existing and potential new editors on the following dates:

  • Wednesday 10 April 3.30-4.30 pm
  • Thursday 18 April 12-1 pm

 

To book for one of these webinars, please complete the registration form at https://forms.office.com/e/eGjKqNVjeF

Quality audit

Many thanks to all of you who have met with me recently to complete or clarify your responses to the quality audit survey at the end of last year.  Work to complete the quality audit for all toolkits published on RDS prior to November last year will continue for the next few months.

Implementation projects

The RDS team is now working with Moray HSCP to evaluate impact of the new RDS toolkit “Preventing progress of diabetes”  (https://preventdiabetes.scot.nhs.uk ) to support people at high risk of diabetes type 2 and those who are candidates for remission. We are looking at the impact of use of the app with SMS prompts on people’s readiness for lifestyle change over an 8 week period. This includes comparing impact in people who have a call with a dietitian in addition to using the app to people who only use the app.

If you have any questions about the content of this newsletter, please contact us on his.decisionsupport@nhs.scot.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

 

Acne

Warning

Acne vulgaris: A common chronic inflammatory skin disorder affecting the pilosebaceous unit (i.e., the hair follicle and sebaceous gland) resulting in blockage of the follicle and immune mediated inflammation. Acne affects males and females of all races and ethnicities. All patients with acne should be offered clear information tailored to their needs and concerns. Consider referring to mental health services if a person with acne experiences significant psychological distress or mental health disorder.  

Treatment/ therapy

Severity* 

*A universally accepted definition of acne severity does not exist. Overall severity is a clinical judgement based on multiple factors including previous treatment response, scarring and family history. Lesion counts are commonly used in research and the definitions provided are based on NICE 2021 guidelines purely as a guide. 

Mild - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules. 

Self care- patients should be encouraged to use a non-alkaline synthetic cleansing product daily, avoid comedogenic products and avoid scratching or picking of lesions 

First line treatment options, taking into account severity and patient preference after a discussion of advantages and disadvantages: 

  • Fixed combination topical Adapalene with topical benzoyl peroxide (any acne severity) or; 
  • Fixed combination topical tretinoin with topical clindamycin (any acne severity) 
  • Fixed combination benzoyl peroxide with topical clindamycin (mild/moderate acne) 
  • Topical Azelaic acid (moderate to severe acne). 

 

Consider benzoyl peroxide monotherapy if above options contraindicated or patient wishes to avoid topical retinoids/antibiotics.  

 

Topical retinoids should not be prescribed in pregnant/breastfeeding women.  

 

*Please see key messages box below* 

Moderate - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules.

Fixed combination topical benzoyl peroxide and topical adapalene OR topical azelaic acid twice daily in addition to an oral antibiotic for 12 weeks such as: 

  • Doxycycline 100mg OD   
  • Lymecycline (Tetralysal 300) 408mg OD 

 

If no improvement after 12 weeks then trial another antibiotic. If improvement noted after 12 weeks can continue for another 12 weeks but ideally not beyond a total of 6 months. Stop antibiotics as soon as possible.  

 

Tetracyclines can cause photosensitivity and are teratogenic. They should be avoided in children <12 years. Oral antibiotics may cause systemic side effects and antimicrobial resistance.  

 

Erythromycin or trimethoprim (unlicensed) can be considered if contraindications/ intolerance to tetracyclines. 

Trimethoprim can cause serious but rare side effects including agranulocytosis and severe cutaneous adverse reactions such as Stevens-Johnson syndrome. 

 

Macrolides are linked with high antimicrobial resistance and are not first line treatments. 

 

Hormonal Treatment Considerations: 

 

  • Progesterone only contraception may exacerbate acne. 
  • The type of progestin used in different combined contraceptive pills differ, as does their anti-androgenic action. For instance, levonorgestrel used in a number of commonly prescribed combined contraceptives has an increased androgenic potential compared with some other progestins. 
  • Ideally combined contraceptives should be used for females with acne who do also require a contraceptive. 
  • For women with polycystic ovary syndrome, treat as per first line management. If this is ineffective consider adding co-cyprindiol (Dianette®) or an alternative combined oral contraceptive.  
  • Those on co-cyprindiol should be reviewed at 6 months to assess need for continuation/other treatment options.  

Severe - For moderate to severe acne this includes people who have either or both of: 35 or more inflammatory lesions (with or without non-inflammatory lesions); 3 or more nodules

Treatment should be started in primary care as per moderate acne (combination oral antibiotics and topical treatment) whilst awaiting appointment with a consultant-led dermatology team for consideration of isotretinoin. 

Referral management

Severity* 

*A universally accepted definition of acne severity does not exist. Overall severity is a clinical judgement based on multiple factors including previous treatment response, scarring and family history. Lesion counts are commonly used in research and the definitions provided are based on NICE 2021 guidelines purely as a guide. 

Mild - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules. 

Can generally be managed in primary care 

Moderate - For mild to moderate acne, this includes people who have 1 or more of: any number of non-inflammatory lesions (comedones); up to 34 inflammatory lesions (with or without non-inflammatory lesions); up to 2 nodules.

Manage in primary care. Consider referral to consultant-led community or secondary care service if: 

- Mild to moderate acne has not responded to 2 completed courses of treatment (topical and oral) antibiotics.  

- Moderate to severe acne which has not responded to previous treatments containing an oral antibiotic. 

Severe - For moderate to severe acne this includes people who have either or both of: 35 or more inflammatory lesions (with or without non-inflammatory lesions); 3 or more nodules

Refer to consultant-led community or secondary care dermatology service in cases of: 

- diagnostic uncertainty  

- acne conglobata 

- nodulocystic acne 

Urgent same day referral should be made for cases of acne fulminans 

Consider referral in those with any severity who have scarring or persistent pigmentary change 

Clinical tips

  • Topical Benzoyl Peroxide (BPO) containing preparations can reduce resistant C. Acnes developing when used alongside topical/oral antibiotics 
  • BPO and topical retinoids cause skin irritation, so should be introduced slowly (low-strength, low-frequency) and should be used alongside hydrating products. Short contact application initially (e.g. application for 1 hour then wash off) can help build skin tolerance. 
  • Do not use systemic monotherapy with a topical antibiotic, monotherapy with an oral antibiotic or topical and oral antibiotics in combination 
  • Spironolactone is an unlicensed treatment for acne in female patients. Practice differs amongst dermatologists but this can be a useful option in some women in whom advice regarding suitability from a dermatologist-led team may be useful. 
  • Consider referral to mental health services if acne is considerably affecting mental wellbeing including those with current/past history of anxiety/self- harm/suicidal ideation/body dysmorphic disorder. 
  • For all patients, regardless of severity, consideration of underlying causes such as drugs/other disease processes should be made with onward referral to specialists such as endocrinologists if deemed necessary.  

ICD search categories

Inflammatory 

ICD11 code - ED80 

Editorial Information

Last reviewed: 24/05/2023

Next review date: 24/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society .

Approved By: Scottish Dermatological Society